Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.

Article Authors: L Morrow, M. Hompesch, H Guthrie, D Chang, D J Chatterjee

no alt text set


To compare the pharmacokinetic (PK) [area under the curve (AUC0–24 hCmax)] and pharmacodynamic (PD) (AUCGIR 0–24 h, GIRmax) properties of single-dose insulin detemir in the presence or absence of steady-state liraglutide (1.8 mg dose) in subjects with type 2 diabetes to determine whether co-administration affected the PK and PD profiles of either therapeutic agent.